We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
+$131M
Cap. Flow %
5.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
CNSY
Cerenome
CNSY
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Miscellaneous 86.57%
2 Healthcare 9.72%
3 Real Estate 2.82%
4 Energy 0.36%
5 Consumer Discretionary 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
276
CALL
Ligand Pharmaceuticals
LGND
$5.51B
– –
-673
Closed -$2.83M
LLY icon
277
CALL
Eli Lilly
LLY
$1.02T
– –
-1,719
Closed -$10.1M
MRK icon
278
CALL
Merck
MRK
$352B
– –
-2,113
Closed -$11.4M
NKTR icon
279
PUT
Nektar Therapeutics
NKTR
$2.3B
– –
-97
Closed -$1.77M
OMER icon
280
Omeros
OMER
$1.23B
– –
-20,000
Closed -$241K
PFE icon
281
CALL
Pfizer
PFE
$156B
– –
-4,533
Closed -$13.8M
PFE icon
282
PUT
Pfizer
PFE
$156B
– –
-685
Closed -$2.09M
PRTA icon
283
CALL
Prothena Corp
PRTA
$438M
– –
-225
Closed -$862K
SPY icon
284
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$801B
– –
-1,338
Closed -$25M
TCRT icon
285
Alaunos Therapeutics
TCRT
$3.73M
– –
-737
Closed -$410K
TCRT icon
286
PUT
Alaunos Therapeutics
TCRT
$3.73M
– –
-10
Closed -$667K
TLPH icon
287
CALL
Talphera
TLPH
$63.8M
– –
-23
Closed -$563K
TMO icon
288
CALL
Thermo Fisher Scientific
TMO
$231B
– –
-1,100
Closed -$13.2M
TMO icon
289
Thermo Fisher Scientific
TMO
$231B
– –
-38,630
Closed -$4.64M
XBI icon
290
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-131,235
Closed -$6.23M
BPTH
291
DELISTED
Bio-Path Holdings Inc
BPTH
– –
-828
Closed -$8.78M
DMK
292
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-868
Closed -$386K
ISEE
293
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-15,944
Closed -$570K
ISEE
294
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-400
Closed -$1.43M
MNTA
295
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-1,729
Closed -$2.01M
MNTA
296
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-18,274
Closed -$213K
MNTA
297
PUT
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-382
Closed -$445K
AVEO
298
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-57,342
Closed -$857K
SGYP
299
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-377,908
Closed -$718K
TSRO
300
DELISTED
TESARO, Inc.
TSRO
– –
-98,500
Closed -$2.63M
9 10 11
12
13

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management deployed $131M of net new capital in Q2 2014, opening 83 new positions and adding to 72 existing holdings. Its largest new stake was Weyerhaeuser: 1,950,977 shares worth $64.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 89% a quarter earlier, followed by Healthcare and Real Estate.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $7.12M trimmed.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.